Biotalys NV
Publication of transparency notification
Publication of transparency notification
Article 14(1) of the Law of 2 May 2007 on the disclosure of large shareholders in issuers whose shares are admitted to trading on a regulated market
Ghent, BELGIUM, June 16, 2025 (GLOBE NEWSWIRE) -- Press release - regulated information
Biotalys NV (Euronext Brussel : BTLS) (the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, announces today, in accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that it has received a transparency notification from Sofinnova Partners SAS.
Sofinnova Partners SAS has announced that, on 11 June 2025, it held 3,719,820 shares of Biotalys NV, representing 9.93% of the total number of voting rights.
The notification dated 12 June 2025 contains the following information:
- Reason for the notification: acquisition or disposal of voting securities or voting rights
- Notification by: a person that notifies alone
- Persons subject to the notification requirement:
- Sofinnova Partners SAS, 7-11 boulevard Haussmann, 75009 Paris, France
- Date on which the threshold was crossed: 11 June 2025
- Threshold that is crossed: 10%
- Denominator: 37,470,062
- Notified details:
Voting rights | Previous notification | After the transaction | |||||
# of voting rights | # of voting rights | % of voting rights | |||||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |||
Sofinnova Partners SAS | 4,226,962 | 3,719,820 | 0 | 9.93 | % | 0.00 | % |
TOTAL | 3,719,820 | 0 | 9.93 | % | 0.00 | % |
Sofinnova Partners SAS is not a controlled entity in the sense of articles 1:14 - 1:16 of the Company and Associations Code.
The transparency notification can be found on www.biotalys.com/investors.
About Biotalys
Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.
For further information, please contact:
Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: IR@biotalys.com
Attachments
- Biotalys_Publication of Transparency Notification_16 June 2025
- Biotalys_Bekendmaking van transparantiemelding_16 juni 2025
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
The Metals Company16.6.2025 22:05:28 CEST | Press release
TMC Announces Appointment of Michael Hess and Alex Spiro to its Board of Directors
PARKEN Sport & Entertainment A/S16.6.2025 21:54:26 CEST | Pressemeddelelse
Der er dags dato konstateret rygter i markedet om en mulig transfer af fodboldspilleren Victor Froholdt
CGTN16.6.2025 19:21:42 CEST | Pressemeddelelse
CGTN: Fra far til søn: De grundlæggende værdier, der viser Xi Jinping vej
CoinShares International Limited16.6.2025 18:27:58 CEST | Press release
CoinShares Announces Exercise of Employee Incentive Plan Options
Siili Solutions Oyj16.6.2025 17:30:00 CEST | Press release
Siili Solutions Plc: Share Repurchase 16.6.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom